Top 10 Oncology Capital Raises and Investors in the U.S. – August 1st-31st, 2026
Several interesting transactions closed in the Oncology sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Rakovina Therapeutics, a biopharmaceutical research company on the development of cancer treatments, received CAD 1.99 million of development capital.
Merger/Acquisition
-
- Endurx Pharmaceuticals, a drug delivery platform that improves treatments of hard-to-treat solid tumors and cancer, was acquired by NanoRx Science.
- Kartos Therapeutics, targeted oncology therapeutics that addresses cancer treatment through novel mechanisms of action, was acquired by Ipsen for $450 million.
- Kashiv BioSciences, pharmaceutical research, and drug delivery services that creates improved versions of known medicines with clinical differentiation, was acquired by Amneal Pharmaceuticals for $1.1 billion.
Later Stage VC
-
- Abcuro, immunomodulatory therapeutics for treating both autoimmunity and cancer, raised $66 million of Series D venture funding in a deal led by New Leaf Venture.
- Duo Oncology, a clinical-stage biotechnology platform that replaces traditional chemotherapy with more precise and tolerable cancer treatments, raised $1.63 million of venture funding in the form of convertible debt financing.
Early Stage VC
-
- INNOVOTEX, targeted oncology therapeutics that treats drug-resistant solid tumors, raised $4.00 million of venture funding in a deal led by Bull Capital.
- Altido Therapeutics, cell-based immunotherapies that treats difficult-to-treat solid tumors, raised venture funding from Mass General Brigham Ventures.
Seed
-
- Bullseye Biodevices, a biosensing platform that enables precise disease detection and targeted drug delivery, raised $1.3 million of seed funding from ABKO.
- Bios Life, an artificial intelligence-powered cancer surveillance platform that provides personalized cancer screening and survivorship care, raised $25 million through a combination of Seed 1 and Seed 2 funding in a deal led by Redmile Group, VSquared Ventures and Kindred Capital.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.











